• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

eXoZymes Inc. - Common Stock (NQ:EXOZ)

11.70 +0.30 (+2.63%)
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about eXoZymes Inc. - Common Stock

< Previous 1 2 Next >
News headline image
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
Today 9:10 EDT
Via ACCESS Newswire
News headline image
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
March 31, 2026
Via ACCESS Newswire
News headline image
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
March 25, 2026
Via ACCESS Newswire
News headline image
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
March 18, 2026
Via ACCESS Newswire
News headline image
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
March 12, 2026
Via ACCESS Newswire
News headline image
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
February 10, 2026
Via ACCESS Newswire
News headline image
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
January 29, 2026
Via ACCESS Newswire
News headline image
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
December 11, 2025
Via ACCESS Newswire
News headline image
eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
November 13, 2025
Via ACCESS Newswire
News headline image
eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
November 13, 2025
Via ACCESS Newswire
News headline image
eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
November 10, 2025
Via ACCESS Newswire
News headline image
CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference
October 30, 2025
Via ACCESS Newswire
News headline image
CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference
October 29, 2025
Via ACCESS Newswire
News headline image
CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference
October 23, 2025
Via ACCESS Newswire
News headline image
Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees
September 30, 2025
Via ACCESS Newswire
News headline image
eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
August 12, 2025
Via ACCESS Newswire
News headline image
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
August 07, 2025
Via ACCESS Newswire
News headline image
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
July 29, 2025
Via ACCESS Newswire
News headline image
eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months
July 22, 2025
Via ACCESS Newswire
News headline image
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
June 26, 2025
Via ACCESS Newswire
News headline image
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast
May 16, 2025
Via ACCESS Newswire
News headline image
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today
May 12, 2025
Via ACCESS Newswire
News headline image
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST
May 07, 2025
Via ACCESS Newswire
News headline image
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health
May 06, 2025
Via ACCESS Newswire
News headline image
Bringing clarity and precision to the cell-free space by introducing exozymes
April 21, 2025
From eXoZymes Inc.
Via GlobeNewswire
News headline image
New to The Street's FOX Business "Late Night T.V." Special Airs Tonight – Show #650 – Featuring Health In Tech CEO Julia Qian (NASDAQ:HIT), BioVie's Dr. Joseph Palumbo (NASDAQ:BIVI), eXoZymes Co-Founder & VP of Research Tyler Korman (EXOZ), and ARRIVE AI
April 14, 2025
Via ACCESS Newswire
News headline image
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
April 10, 2025
From eXoZymes Inc.
Via GlobeNewswire
News headline image
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
April 02, 2025
From eXoZymes Inc.
Via GlobeNewswire
News headline image
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
April 02, 2025
From eXoZymes Inc.
Via GlobeNewswire
News headline image
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
March 26, 2025
From eXoZymes Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap